HALOA: Cardiac Coherence With CPAP for Obstructive Sleep Apnea (HALOA)
Effect of Adding Cardiac Coherence to Continuous Positive Airway Pressure in Patients With Obstructive Sleep Apnea: A Multicenter Randomized Delayed-Start Controlled Study
This multicenter study will evaluate whether adding cardiac coherence breathing sessions to continuous positive airway pressure (CPAP) improves sleep quality in adults with newly diagnosed obstructive sleep apnea who are starting CPAP. Approximately 180 participants will be randomly assigned to one of two groups. Both groups will start treatment with the HALOA CPAP system. In one group, the cardiac coherence module will be activated at the start of treatment. In the other group, participants will use CPAP alone for 8 weeks before the module is activated.
Sleep quality will be assessed at study entry, at 8 weeks, and at 16 weeks using the Pittsburgh Sleep Quality Index. The primary comparison will assess the change in sleep quality from study entry to week 8 between the two groups. Secondary assessments will include daytime sleepiness, insomnia symptoms, anxiety and depression symptoms, treatment satisfaction, usability of the cardiac coherence module, CPAP use, and heart-rate variability when polysomnography recordings are available.
Visão geral do estudo
Status
Condições
Descrição detalhada
Obstructive sleep apnea is commonly treated with continuous positive airway pressure (CPAP). However, some patients have difficulty adhering to CPAP or experience persistent sleep-related symptoms. Cardiac coherence is a guided breathing practice intended to support relaxation and emotional regulation. The HALOA system combines CPAP treatment with a cardiac coherence module. This study will assess whether access to this module from the start of CPAP treatment improves subjective sleep quality compared with starting the module after an initial period of CPAP alone.
This is a prospective, multicenter, randomized, open-label, delayed-start controlled study. Approximately 180 adults with newly diagnosed obstructive sleep apnea and an indication for CPAP will be enrolled at 11 planned centers. Participants will be randomly assigned in equal numbers to one of two groups.
All participants will begin CPAP treatment using the HALOA system and will receive usual CPAP care. Participants in the immediate-intervention group will have the cardiac coherence module activated at study entry and will receive guidance on its use. Participants in the delayed-intervention group will use CPAP without cardiac coherence for the first 8 weeks. After the week 8 assessment, the module will be activated and participants will receive guidance on its use.
Study assessments will take place at baseline, week 8, and week 16. The primary outcome is the change in the global Pittsburgh Sleep Quality Index (PSQI) score from baseline to week 8, comparing the two randomized groups. The week 8 assessment provides the controlled comparison before participants in the delayed-intervention group begin cardiac coherence. Changes in PSQI from week 8 to week 16 in the delayed-intervention group will also be assessed to explore the effect after the module is introduced.
Secondary assessments will include daytime sleepiness using the Epworth Sleepiness Scale, insomnia symptoms using the Insomnia Severity Index, and anxiety and depression symptoms using the Hospital Anxiety and Depression Scale. Patient satisfaction will be assessed using the CSQ-8 and a study-specific questionnaire. Usability of the cardiac coherence module will be assessed using the System Usability Scale. CPAP adherence will be evaluated using device data, including hours of use and the proportion of participants meeting the protocol-defined adherence threshold. Heart-rate variability indices will be evaluated from polysomnography recordings when available.
Participants will be adults with obstructive sleep apnea diagnosed by polysomnography within the 3 months before inclusion and for whom CPAP treatment is indicated. The protocol lists recent CPAP or mandibular advancement device treatment, refusal of or contraindication to CPAP, inability to use the cardiac coherence device, and specified medical, psychiatric, or other circumstances among the non-inclusion criteria.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: François FB Bughin, Md, PhD
- Número de telefone: 0033761783081
- E-mail: fbughin@hotmail.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 years or older.
- Obstructive sleep apnea diagnosed according to ICSD-3 criteria by polysomnography performed within 3 months before study inclusion.
- Indication for CPAP treatment according to current recommendations: apnea-hypopnea index (AHI) ≥30 events/hour, or AHI ≥15 events/hour with severe cardiovascular or respiratory comorbidity.
- Written informed consent.
Exclusion Criteria:
- CPAP or mandibular advancement device treatment within the 3 months before inclusion.
- Refusal of CPAP treatment.
- Contraindication to CPAP treatment.
- Unstable psychiatric disorder or substance-use disorder.
- Technical inability to use the cardiac coherence device.
- Not affiliated with, or not a beneficiary of, a social security system.
- Deprivation of liberty by judicial or administrative decision.
- Legal protective measure, including guardianship or curatorship.
- Pregnancy, childbirth, or breastfeeding.
- Language barrier preventing participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Immediate cardiac coherence with CPAP
Participants will start HALOA CPAP at study inclusion. The cardiac coherence breathing module will be activated from the start of treatment, with guidance on its use. Participants will be assessed at baseline, week 8, and week 16. |
CPAP treatment using the HALOA system, initiated at study inclusion in both groups and provided as part of usual care. Guided cardiac coherence breathing sessions using the module integrated with the HALOA system. The module is activated at study inclusion in the experimental group and after the week 8 assessment in the active comparator group. |
|
Comparador Ativo: Delayed cardiac coherence with CPAP
Participants will start HALOA CPAP at study inclusion and use it without the cardiac coherence module for 8 weeks. After the week 8 assessment, the module will be activated and guidance on its use provided. Participants will be assessed at baseline, week 8, and week 16. |
CPAP treatment using the HALOA system, initiated at study inclusion in both groups and provided as part of usual care. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Global Pittsburgh Sleep Quality Index (PSQI) Score
Prazo: Baseline to week 8
|
Absolute change in the global PSQI score from baseline (V1) to week 8 (V2), comparing the randomized groups. PSQI scores range from 0 to 21; higher scores indicate poorer sleep quality. |
Baseline to week 8
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in PSQI Score After Delayed Initiation of Cardiac Coherence
Prazo: Week 8 to week 16
|
Absolute change in global PSQI score from week 8 (V2) to week 16 (V3) in the delayed-intervention group, after the cardiac coherence module is activated. |
Week 8 to week 16
|
|
Change in Daytime Sleepiness
Prazo: Baseline, week 8, and week 16
|
Changes in Epworth Sleepiness Scale (ESS) |
Baseline, week 8, and week 16
|
|
Change in insomnia symptoms
Prazo: Baseline, week 8, and week 16
|
Changes in Insomnia Severity Index (ISI) |
Baseline, week 8, and week 16
|
|
Change in depression symptoms
Prazo: Baseline, week 8, and week 16
|
Changes in Hospital Anxiety and Depression Scale anxiety and depression subscale scores (HADS-A and HADS-D). |
Baseline, week 8, and week 16
|
|
Patient Satisfaction
Prazo: Baseline, week 8, and week 16, as applicable
|
Patient satisfaction measured using the Client Satisfaction Questionnaire (CSQ-8) and the study-specific S-HALOA-CC questionnaire. S-HALOA-CC results will be considered exploratory. |
Baseline, week 8, and week 16, as applicable
|
|
Usability of the Cardiac Coherence Module
Prazo: Week 8 for the immediate-intervention group and week 16 for the delayed-intervention group
|
Usability measured using the System Usability Scale (SUS) after exposure to the cardiac coherence module. |
Week 8 for the immediate-intervention group and week 16 for the delayed-intervention group
|
|
CPAP Adherence
Prazo: At weeks 8 and 16; device use assessed over the 7-day and 30-day periods before each visit
|
Mean nightly CPAP use and the proportion of participants meeting the protocol-defined adherence threshold of at least 4 hours per night on at least 70% of nights. |
At weeks 8 and 16; device use assessed over the 7-day and 30-day periods before each visit
|
|
Heart-Rate Variability
Prazo: Baseline and week 16, when recordings are available
|
Changes in time-domain and frequency-domain heart-rate variability indices derived from polysomnography recordings, when follow-up recordings are available. |
Baseline and week 16, when recordings are available
|
|
Clinically Meaningful Improvement in Sleep Quality
Prazo: Baseline to week 8, week 8 to week 16, and baseline to week 16
|
Proportion of participants with a decrease of at least 3 points in global PSQI score over the specified assessment interval. |
Baseline to week 8, week 8 to week 16, and baseline to week 16
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Herhaus B, Kalin A, Gouveris H, Petrowski K. Mobile Heart Rate Variability Biofeedback Improves Autonomic Activation and Subjective Sleep Quality of Healthy Adults - A Pilot Study. Front Physiol. 2022 Feb 17;13:821741. doi: 10.3389/fphys.2022.821741. eCollection 2022.
- Laborde S, Hosang T, Mosley E, Dosseville F. Influence of a 30-Day Slow-Paced Breathing Intervention Compared to Social Media Use on Subjective Sleep Quality and Cardiac Vagal Activity. J Clin Med. 2019 Feb 6;8(2):193. doi: 10.3390/jcm8020193.
- Stepnowsky C, Zamora T, Edwards C. Does Positive Airway Pressure Therapy Result in Improved Sleep Quality? Health (Irvine Calif). 2014 Oct;6(18):2416-2424. doi: 10.4236/health.2014.618278.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Doenças Respiratórias
- Distúrbios Respiratórios
- Distúrbios do Sono Vigília
- Apnéia
- Distúrbios do Sono Intrínsecos
- Dissônias
- Síndromes da Apneia do Sono
- Comportamento
- Comportamento de saúde
- Apnéia do Sono, Obstrutiva
- Distúrbios de Iniciação e Manutenção do Sono
- Adesão e Cumprimento do Tratamento
Outros números de identificação do estudo
- 26.01725.000477
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The sponsor has not yet determined whether individual participant data and the corresponding data dictionary will be made available to other researchers. The plan will be updated once a decision has been made.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .